يعرض 1 - 10 نتائج من 43 نتيجة بحث عن '"Acuaporina 4"', وقت الاستعلام: 1.55s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    رسالة جامعية
  6. 6
  7. 7
    دورية أكاديمية

    المساهمون: Trillo-Contreras,JL, Toledo-Aral,JJ, Villadiego,J, Echevarría,M Institute of Biomedicine of Seville-IBiS, University Hospital Virgen del Rocío, CSIC, University of Seville, Seville, Spain. Trillo-Contreras,JL, Echevarría,M Department of Medical Physiology and Biophysics, University of Seville, Seville, Spain. Toledo-Aral,JJ, Villadiego,J Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain, This study was supported by grants FIS: PI16/00493 and PI19/01096 from the Spanish Ministry of Economy and Competitiveness, co-financed by the Carlos III Health Institute (ISCIII) and European Regional Development Fund (FEDER).

    وصف الملف: application/pdf

    العلاقة: https://www.mdpi.com/1422-0067/22/18/9745/htmTest; Trillo-Contreras JL, Toledo-Aral JJ, Villadiego J, Echevarría M. Aquaporin-4 Mediates Permanent Brain Alterations in a Mouse Model of Hypoxia-Aged Hydrocephalus. Int J Mol Sci. 2021 Sep 9;22(18):9745; http://hdl.handle.net/10668/4403Test; PMC8471142

  8. 8
    دورية أكاديمية

    المساهمون: Marazuela,P, Bonaterra-Pastra,A, Faura,J, Penalba,A, Pizarro,J, Montaner,J, Hernández-Guillamon,M Neurovascular Research Laboratory, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain. Pancorbo, O, Rodríguez-Luna,D Stroke Unit, Department of Neurology, Vall d’Hebron Hospital, Barcelona, Spain. Vert,C, Rovira,A Neuroradiology, Department of Radiology, Vall d’Hebron Hospital, Barcelona, Spain. Pujadas,F Dementia Unit, Neurology Department, Vall d’Hebron Hospital, Barcelona, Spain. Freijo,MM Neurovascular Group, Biocruces Health Research Institute, Barakaldo, Spain. Tur,S Neurology, Son Espases University Hospital, Balearic Islands, Spain. Martínez-Zabaleta,M Department of Neurology, Donostia University Hospital, San Sebastián, Spain. Cardona Portela,P Department of Neurology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain. Vera,R Stroke Unit, Department of Neurology, Ramon y Cajal University Hospital, Madrid, Spain. Lebrato-Hernández,L Stroke Unit, Virgen del Rocío University Hospital, Sevilla, Spain. Arenillas,JF Stroke Program, Department of Neurology, Hospital Clínico Universitario, Valladolid, Spain Arenillas,JF Clinical Neurosciences Research Group, Department of Medicine, University of Valladolid, Valladolid, Spain. Pérez-Sánchez,S, Montaner,J Department of Neurology, Virgen Macarena University Hospital, Sevilla, Spain. Montaner,J Stroke Research Program, Institute of Biomedicine of Sevilla, IBiS, Virgen del Rocío University Hospital, University of Sevilla, Sevilla, Spain., This research was funded by the Instituto de Salud Carlos III (ISCIII), (PI17/00275 and PI20/00465), co-financed by the European Regional Development Fund FEDER. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. was supported by the Miguel Servet programme, ISCIII, Spain (CPII17/00010). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.

    مصطلحات موضوعية: Aquaporin 4, Cerebral amyloid angiopathy, Intracerebral hemorrhage, Magnetic resonance imaging markers, Functional outcome, Enzyme-linked immunosorbent assay, Acuaporina 4, Angiopatía amiloide cerebral, Hemorragia cerebral, Imagen por resonancia magnética, Ensayo de inmunoadsorción enzimática, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans, Medical Subject Headings::Persons::Persons::Age Groups::Adult::Aged, Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Membrane Transport Proteins::Ion Channels::Porins::Aquaporins::Aquaporin 4, Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Specialty Uses of Chemicals::Surface-Active Agents::Immunosorbents, Medical Subject Headings::Diseases::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Intracranial Arterial Diseases::Cerebral Arterial Diseases::Cerebral Amyloid Angiopathy, Medical Subject Headings::Diseases::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Intracranial Hemorrhages::Cerebral Hemorrhage, Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Magnetic Resonance Imaging, and Proteins::Peptides::Amyloid beta-Peptides, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Immunologic Techniques::Immunoassay::Immunoenzyme Techniques::Enzyme-Linked Immunosorbent Assay

    وصف الملف: application/pdf

    العلاقة: https://www.mdpi.com/2077-0383/10/5/989Test; Marazuela P, Bonaterra-Pastra A, Faura J, Penalba A, Pizarro J, Pancorbo O, et al. Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage. J Clin Med. 2021 Mar 2;10(5):989; http://hdl.handle.net/10668/4571Test; PMC7957864

  9. 9
    دورية أكاديمية

    المصدر: Case reports; Vol. 5 No. 1 (2019); 11-18 ; Case reports; Vol. 5 Núm. 1 (2019); 11-18 ; Case reports; v. 5 n. 1 (2019); 11-18 ; 2462-8522

    وصف الملف: application/pdf; text/html; application/xml

    العلاقة: https://revistas.unal.edu.co/index.php/care/article/view/74943/69820Test; https://revistas.unal.edu.co/index.php/care/article/view/74943/70681Test; https://revistas.unal.edu.co/index.php/care/article/view/74943/71775Test; Rao C, Fox S, Desai SS. Myointimal Hyperplasia in a Patient with Neuromyelitis Optica (Devic's Disease) after the Creation of an Arteriovenous Graft. Case Rep Neurol. 2017;9(3):252-5. http://doi.org/gczkg7Test.; Mealy MA, Wingerchuk DM, Greenberg BM, levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176-80. http://doi.org/cx6bTest.; Alvarenga MP, Schimidt S, Alvarenga RP. Epidemiology of neuromyelitis optica in Latin America. Mult Scler J Exp Transl Clin. 2017;3(3):2055217317730098. http://doi.org/cx6cTest.; Derle E, Güneş HN, Konuşkan B, Tuncer-Kurne A. Neuromyelitis optica in children: a review of the literature. Turk J Pediatr. 2014;56(6):573-80.; Bradl M, Reindl M, Lassmann H. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr Opin Neurol. 2018;31(3):325-33. http://doi.org/cx6dTest.; Guo Y, Weigand SD, Popescu BF, Lennon VA, Parisi JE, Pittock SJ, et al. Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathol. 2017;133(4):597-612. http://doi.org/f9xmksTest.; Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12. http://doi.org/cs8v2hTest.; Jacob A. Neuromyelitis optica - an update: 2007-2009. Ann Indian Acad Neurol. 2009;12(4):231-7. http://doi.org/fjpzh8Test.; Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. http://doi.org/cx6fTest.; Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71(3):276-83. http://doi.org/f5vmjtTest.; Gombolay GY, Chitnis T. Pediatric Neuromyelitis Optica Spectrum Disorders. Curr Treat Options Neurol. 2018;20(6):19. http://doi.org/gdngqcTest.; Baghbanian SM, Asgari N, Sahraian MA, Moghadasi AN. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. J Neurol Sci. 2018;388:222-31. http://doi.org/gdhv38Test.; Alves Do Rego C, Collongues N. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Rev Neurol (Paris). 2018;174(6):458-70. http://doi.org/gdrqj3Test.; Bouzar M, Daoudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, et al. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. J Neurol Sci. 2017;381:240-4. http://doi.org/cx6gTest.; Magaña SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology. 2009;72(8):712-7. http://doi.org/b6dgg5Test.; Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. http://doi.org/f7jm87Test.; Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165-73. http://doi.org/f65d47Test.; Matsushita T, Isobe N, Piao H, Matsuoka T, Ishizu T, Doi H, et al. Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. J Neurol Sci. 2010;291(1-2):37-43. http://doi.org/cv27wxTest.; Absoud M, Lim MJ, Appleton R, Jacob A, Kitley J, Leite MI, et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry. 2015;86(4):470-2. http://doi.org/f66fbgTest.; Reyes MA, Navas-Granados AV. Ramírez SF. Espectro de neuromielitis óptica en Colombia, primera caracterización clínico imagenológica en tres centros de Bogotá. Acta Neurol Colomb. 2016;32(3):190-202; Pinzón A, Echeverry T, Rodríguez AB. Neuromielitis óptica (enfermedad de Devic). Acta Médica Colombiana. 2010;35(1):21-5.; Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, et al. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord. 2012;1(4):180-7. http://doi.org/cx6hTest.; Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324-30. http://doi.org/f5vn2vTest.; Tenembaum SN. Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents. Clin Neurol Neurosurg. 2013;115(Suppl 1):S21-9. http://doi.org/f5q4chTest.; https://revistas.unal.edu.co/index.php/care/article/view/74943Test

  10. 10
    دورية أكاديمية